Genmab jumps more than 25% intraday to a record high as U.S. biotech stocks advance
Genmab rose more than 25% during intraday trading and hit a record high, according to MSX.COM data. The move came after the biotech company released updated results from its Phase III LiGeR-HN1 study of Petosemtamab, showing that the combination therapy reduced the risk of death by 50% in patients with head and neck squamous cell carcinoma. Other U.S.-listed biotech names also moved higher. Twist Bioscience gained more than 9%, Recursion Pharmaceuticals climbed more than 8%, and Moderna rose more than 4%. The session reflected broad strength across the U.S. biotechnology segment.








